Johnson Matthey has beefed up its ligand manufacturing capabilities in the US citing the pharmaceutical manufacturing industry as a key target.
The firm has increased its manufacturing capacity to 100kg with the main focus being the production of Buchwald ligands, which are used in numerous coupling reactions in the drug production process.
A company spokeswoman told in-Pharmatechnologist.com that Buchwald ligands – which were developed by researchers at the Massachusetts Institute of Technology in the US – have a wide range of applications in the drug industry, including in catalyst production.
“The combination of Buchwald phosphine ligands such as X-Phos, S-Phos, Ru-Phos or Brett-Phos, with one of a number of palladium catalyst precursors has proven to be a convenient process for the in situ generation of active catalysts.
“These catalysts have demonstrated superior results in a broad range of applications including the well-known coupling reactions Heck-Mizoroki, Suzuki-Miyaura, Sonogashira, Buchwald-Hartwig, and alpha arylations,” she added.
This was echoed by Johnson Matthey Catalysis commercial manager Daren Bryce, who said that: “The ability to offer Buchwald ligands from research through to commercial scale creates a unique, global position in the market that complements Johnson Matthey’s wide range of catalyst technologies
The US capacity expansion follows the completion of work on the firm’s new manufacturing facility in Taloja, India.
The expansion also follows just a few months after Johnson Matthey started a review of its active pharmaceutical ingredient (API) business.
Further details were not provided, however the decision to review fits with comments the firm made in November last year when it said unspecified market changes had impacted the performance of its Scotland based API unit, Macfarlan Smith.
In addition to opiate alkaloid producer Macfarlan Smith, the firm’s API business includes Johnson Matthey Pharmaceutical Materials and Services based in New Jersey US which makes ingredients for pain management and attention-deficit hyperactivity disorder (ADHD).
Johnson Matthey declined to discuss the strategy when asked by in-Pharmatechnologist.com.